Antitumor Activity of a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma is a research paper published in Pharmaceutics (2024). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute of the National Institutes of Health
Grant: R21CA267381
National Cancer Institute of the National Institutes of Health
Grant: R21CA270716
National Cancer Institute of the National Institutes of Health
Grant: RP210119
National Cancer Institute of the National Institutes of Health
Grant: RP220169
National Cancer Institute of the National Institutes of Health
Grant: RP210092
National Cancer Institute of the National Institutes of Health
Grant: T32 GM139801
National Institutes of Health
Grant: 5T32GM139801-02
Training Interdisciplinary Pharmacology Scientists (TIPS)
National Institutes of Health
Grant: 5R21CA267381-02
LGR5 antibody drug conjugate for the treatment of neuroblastoma
National Institutes of Health
Grant: 1R21CA270716-01
Novel Antibody-Drug Conjugate Combination Therapy for Treating Colorectal Cancer
Fields of Study
Keywords
Sustainable Development Goals